Cargando…
Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Microbiological Society of Korea
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493534/ https://www.ncbi.nlm.nih.gov/pubmed/34613605 http://dx.doi.org/10.1007/s12275-021-1367-2 |
_version_ | 1784579130301349888 |
---|---|
author | Kim, Eun-Ha Kim, Young-il Jang, Seung-Gyu Im, Minju Jeong, Kyeongsoo Choi, Young Ki Han, Hae-Jung |
author_facet | Kim, Eun-Ha Kim, Young-il Jang, Seung-Gyu Im, Minju Jeong, Kyeongsoo Choi, Young Ki Han, Hae-Jung |
author_sort | Kim, Eun-Ha |
collection | PubMed |
description | The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with hyperferritinemia and COVID-19. In this study, we aimed to determine the antiviral effects of hPH against SARS-CoV-2 in vitro and in vivo models and compared with Remdesivir, an FDA-approved drug for COVID-19 treatment. To assess whether hPH inhibited SARS-CoV-2 replication, we determined the CC(50), EC(50), and selective index (SI) in Vero cells by infection with a SARS-CoV-2 at an MOI of 0.01. Further, groups of ferrets infected with 10(5.8) TCID(50)/ml of SARS-CoV-2 and treated with hPH at 2, 4, 6 dpi, and compared their clinical manifestation and virus titers in respiratory tracts with PBS control-treated group. The mRNA expression of immune-related cytokines was determined by qRT-PCR. hPH treatment attenuated virus replication in a dose-dependent manner in vitro. In a ferret infection study, treatment with hPH resulted in minimal bodyweight loss and attenuated virus replication in the nasal wash, turbinates, and lungs of infected ferrets. In addition, qRT-PCR results revealed that the hPH treatment remarkably upregulated the gene expression of type I (IFN-α and IFN-β) and II (IFN-γ) IFNs in SARS-CoV-2 infected ferrets. Our data collectively suggest that hPH has antiviral efficacy against SARS-CoV-2 and might be a promising therapeutic agent for the treatment of SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-8493534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Microbiological Society of Korea |
record_format | MEDLINE/PubMed |
spelling | pubmed-84935342021-10-06 Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model Kim, Eun-Ha Kim, Young-il Jang, Seung-Gyu Im, Minju Jeong, Kyeongsoo Choi, Young Ki Han, Hae-Jung J Microbiol Virology The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with hyperferritinemia and COVID-19. In this study, we aimed to determine the antiviral effects of hPH against SARS-CoV-2 in vitro and in vivo models and compared with Remdesivir, an FDA-approved drug for COVID-19 treatment. To assess whether hPH inhibited SARS-CoV-2 replication, we determined the CC(50), EC(50), and selective index (SI) in Vero cells by infection with a SARS-CoV-2 at an MOI of 0.01. Further, groups of ferrets infected with 10(5.8) TCID(50)/ml of SARS-CoV-2 and treated with hPH at 2, 4, 6 dpi, and compared their clinical manifestation and virus titers in respiratory tracts with PBS control-treated group. The mRNA expression of immune-related cytokines was determined by qRT-PCR. hPH treatment attenuated virus replication in a dose-dependent manner in vitro. In a ferret infection study, treatment with hPH resulted in minimal bodyweight loss and attenuated virus replication in the nasal wash, turbinates, and lungs of infected ferrets. In addition, qRT-PCR results revealed that the hPH treatment remarkably upregulated the gene expression of type I (IFN-α and IFN-β) and II (IFN-γ) IFNs in SARS-CoV-2 infected ferrets. Our data collectively suggest that hPH has antiviral efficacy against SARS-CoV-2 and might be a promising therapeutic agent for the treatment of SARS-CoV-2 infection. The Microbiological Society of Korea 2021-10-06 2021 /pmc/articles/PMC8493534/ /pubmed/34613605 http://dx.doi.org/10.1007/s12275-021-1367-2 Text en © The Microbiological Society of Korea 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Virology Kim, Eun-Ha Kim, Young-il Jang, Seung-Gyu Im, Minju Jeong, Kyeongsoo Choi, Young Ki Han, Hae-Jung Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model |
title | Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model |
title_full | Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model |
title_fullStr | Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model |
title_full_unstemmed | Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model |
title_short | Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model |
title_sort | antiviral effects of human placenta hydrolysate (laennec(®)) against sars-cov-2 in vitro and in the ferret model |
topic | Virology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493534/ https://www.ncbi.nlm.nih.gov/pubmed/34613605 http://dx.doi.org/10.1007/s12275-021-1367-2 |
work_keys_str_mv | AT kimeunha antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel AT kimyoungil antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel AT jangseunggyu antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel AT imminju antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel AT jeongkyeongsoo antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel AT choiyoungki antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel AT hanhaejung antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel |